SEfficacy and safety of apatinib in the treatment of patients with platinum‑resistant ovarian cancer: A systematic review and network meta‑analysis

Wang,Wei; Liu,Fayong; Qiu,Shan; Jiao,Yan; Zhu,Yan

doi:10.3892/etm.2024.12665

SEfficacy and safety of apatinib in the treatment of patients with platinum‑resistant ovarian cancer: A systematic review and network meta‑analysis

Authors:
- Wei Wang
- Fayong Liu
- Shan Qiu
- Yan Jiao
- Yan Zhu
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Xiantao Maternal and Child Health Hospital, Xiantao, Hubei 433000, P.R. China, Department of Obstetrics and Gynecology, Maternity Hospital of Diarete Province, Diarete, Diarete 14000, Algeria, Department of Obstetrics and Gynecology, Zaoyang First People's Hospital, Zaoyang, Hubei 441200, P.R. China, Department of Obstetrics and Gynecology, Xiangyang Central Center Hospital, Xiangyang, Hubei 441000, P.R. China
Published online on: July 26, 2024 https://doi.org/10.3892/etm.2024.12665
Article Number: 376
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

At present, the optimal therapeutic approach for the treatment of platinum‑resistant recurrent ovarian cancer remains to be fully elucidated. The present systematic review and network meta‑analysis aimed to elucidate the relative efficacy and safety of apatinib, administered either as monotherapy or in conjunction with chemotherapy, compared with chemotherapy alone, for the treatment of platinum‑resistant recurrent ovarian cancer. The PubMed, Embase and Wanfang Data electronic databases were searched, where the search spanned from the conception of the databases until April 2023. A quality evaluation was conducted and R software was used for network meta‑analysis. Following inclusion and exclusion criteria screening, the present analysis included 17 clinical trials, combining data from 1,228 patients with platinum‑resistant recurrent ovarian cancer categorized into the following three treatment cohorts: i) 555 patients who received apatinib plus chemotherapy; ii) 229 patients who received apatinib alone; and iii) 444 patients who underwent conventional chemotherapy. Results of the present study demonstrated that the co‑administration of apatinib with either tegiol [odds ratio (OR), 2.54; 95% CI, 1.06‑6.11] or etoposide (OR, 2.12; 95% CI, 1.20‑3.74) significantly improved the objective response rate (ORR) compared with that following apatinib monotherapy. By contrast, gemcitabine monotherapy resulted in inferior ORR efficacy compared with that following apatinib (OR, 0.47; 95% CI, 0.23‑0.95). In addition, combinations of apatinib with etoposide (OR, 1.32; 95% CI, 1.06‑1.64) or paclitaxel (OR, 1.52; 95% CI, 1.04‑2.23) demonstrated a significantly improved disease control rates (DCR) compared with those following apatinib alone. According to the area under the cumulative ranking analysis, apatinib and paclitaxel in combination was the most efficacious treatment modality in terms of DCR. In terms of safety, the incidence of adverse events, such as hand‑foot syndrome [relative risk (RR), 4.23; 95% CI, 1.80‑9.95] and hypertension (RR, 4.80; 95% CI, 1.53‑15.05), was found to be significantly higher in patients treated with apatinib‑containing therapies, compared with those treated with chemotherapy alone. Consequently, the present meta‑analysis highlighted the potential of apatinib, particularly in combination with chemotherapy, as a therapeutic strategy for patients with platinum‑resistant recurrent ovarian cancer.

View Figures

View References

1	Cao W, Chen HD, Yu YW, Li N and Chen WQ: Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 134:783–791. 2021.PubMed/NCBI View Article : Google Scholar
2	Berek JS and Bast RC Jr: Epithelial ovarian cancer. In: Holland-Frei Cancer Medicine. 6th edition, BC Decker, 2003.
3	Moore KN, Bookman M, Sehouli J, Miller A, Anderson C, Scambia G, Myers T, Taskiran C, Robison K, Mäenpää J, et al: Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: Placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol. 39:1842–1855. 2021.PubMed/NCBI View Article : Google Scholar
4	Rinne N, Christie EL, Ardasheva A, Kwok CH, Demchenko N, Low C, Tralau-Stewart C, Fotopoulou C and Cunnea P: Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer. Cancer Drug Resist. 4:573–595. 2021.PubMed/NCBI View Article : Google Scholar
5	Gaona-Luviano P, Medina-Gaona LA and Magaña-Pérez K: Epidemiology of ovarian cancer. Chin Clin Oncol. 9(47)2020.PubMed/NCBI View Article : Google Scholar
6	Kuroki L and Guntupalli SR: Treatment of epithelial ovarian cancer. BMJ. 371(m3773)2020.PubMed/NCBI View Article : Google Scholar
7	Kurnit KC, Fleming GF and Lengyel E: Updates and new options in advanced epithelial ovarian cancer treatment. Obstet Gynecol. 137:108–121. 2021.PubMed/NCBI View Article : Google Scholar
8	Lheureux S, Braunstein M and Oza AM: Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 69:280–304. 2019.PubMed/NCBI View Article : Google Scholar
9	Dasari S and Bernard Tchounwou P: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014.PubMed/NCBI View Article : Google Scholar
10	Falzone L, Bordonaro R and Libra M: SnapShot: Cancer chemotherapy. Cell. 186:1816–1816.e1811. 2023.
11	Zhang C, Xu C, Gao X and Yao Q: Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics. 12:2115–2132. 2022.PubMed/NCBI View Article : Google Scholar
12	Wang H, Li Y, Wang Y, Shang X, Yan Z, Li S and Bao W: Cisplatin-induced PANDAR-Chemo-EVs contribute to a more aggressive and chemoresistant ovarian cancer phenotype through the SRSF9-SIRT4/SIRT6 axis. J Gynecol Oncol. 35(e13)2024.PubMed/NCBI View Article : Google Scholar
13	Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, et al: Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 451:1116–1120. 2008.PubMed/NCBI View Article : Google Scholar
14	Shen DW, Pouliot LM, Hall MD and Gottesman MM: Cisplatin resistance: A cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 64:706–721. 2012.PubMed/NCBI View Article : Google Scholar
15	Chen Z, Xiao Z, Tian W, Li Z and Wu T: Two enhances the Cisplatin sensitivity of cervical cancer cells via suppression of c-MET expression. Iran J Public Health. 52:1476–1486. 2023.PubMed/NCBI View Article : Google Scholar
16	Xia L, Peng J, Lou G, Pan M, Zhou Q, Hu W, Shi H, Wang L, Gao Y, Zhu J, et al: Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: Results from an open-label, multicenter phase 2 basket study. J Immunother Cancer. 10(e003831)2022.PubMed/NCBI View Article : Google Scholar
17	Trillsch F, Mahner S, Czogalla B, Rottmann M, Chekerov R, Braicu EI, Oskay-Öczelik G, Wimberger P, Richter R and Sehouli J: Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: An analysis of three prospective trials from the NOGGO study group. J Gynecol Oncol. 32(e37)2021.PubMed/NCBI View Article : Google Scholar
18	Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard IL, Richardson GE, Sessa C, Yonemori K, Banerjee S, et al: Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): An open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 22:1034–1046. 2021.PubMed/NCBI View Article : Google Scholar
19	Oronsky B, Ray CM, Spira AI, Trepel JB, Carter CA and Cottrill HM: A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer. Med Oncol. 34:1–7. 2017.PubMed/NCBI View Article : Google Scholar
20	Wolford JE, Bai J, Moore KN, Kristeleit R, Monk BJ and Tewari KS: Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma. Gynecol Oncol. 157:500–507. 2020.PubMed/NCBI View Article : Google Scholar
21	Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Cristea M, DeRosa M, Eisenhauer EL, et al: Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 19:191–226. 2021.PubMed/NCBI View Article : Google Scholar
22	McMullen M, Madariaga A and Lheureux S: New approaches for targeting platinum-resistant ovarian cancer. In: Seminars in cancer biology Elsevier, pp167-181, 2021.
23	Nero C, Ciccarone F, Pietragalla A, Duranti S, Daniele G, Salutari V, Carbone MV, Scambia G and Lorusso D: Ovarian cancer treatments strategy: Focus on PARP inhibitors and immune check point inhibitors. Cancers (Basel). 13(1298)2021.PubMed/NCBI View Article : Google Scholar
24	Eskander RN and Tewari KS: Incorporation of anti- angiogenesis therapy in the management of advanced ovarian carcinoma-mechanistics, review of phase III randomized clinical trials, and regulatory implications. Gynecol Oncol. 132:496–505. 2014.PubMed/NCBI View Article : Google Scholar
25	Chen M, Wang X and Zhang J: Efficacy and safety of apatinib in platinum-resistant recurrent ovarian cancer. China Modern Doctor. 57:74–77, 81. 2019.
26	Chen W, Li Z, Zheng Z and Wu X: Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: A single-center retrospective study. Cancer Med. 9:5899–5907. 2020.PubMed/NCBI View Article : Google Scholar
27	Chu C and Huang Q: Efficacy and safety of apatinib in the chemotherapy of recurrent platinum resistant ovarian cancer. Chin J N Drugs. 29:299–302. 2020.PubMed/NCBI View Article : Google Scholar
28	Geng A, Yang H, Wang Z and Wu C: Apatinib plus paclitaxel versus paclitaxel monotherapy for platinum-resistant recurrent ovarian cancer treatment: A retrospective cohort study. J Clin Pharm Ther. 47:2264–2273. 2022.PubMed/NCBI View Article : Google Scholar
29	Miao M, Deng G, Luo S, Zhou J, Chen L, Yang J, He J, Li J, Yao J, Tan S and Tang J: A phase II study of apatinib in patients with recurrent epithelial ovarian cancer. Gynecol Oncol. 148:286–290. 2018.PubMed/NCBI View Article : Google Scholar
30	Lin Y, Qin S, Li Z, Yang H, Fu W, Li S, Chen W, Gao Z, Miao W, Xu H, et al: Apatinib vs placebo in patients with locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: The REALITY randomized clinical trial. JAMA Oncol. 8:242–250. 2022.PubMed/NCBI View Article : Google Scholar
31	Huang Q, Chu C, Tang J and Dai Z: Efficacy and safety of apatinib combined with etoposide in patients with recurrent platinum-resistant epithelial ovarian cancer: A retrospective study. J Cancer. 11:5353–5358. 2020.PubMed/NCBI View Article : Google Scholar
32	Lan CY, Wang Y, Xiong Y, Li JD, Shen JX, Li YF, Zheng M, Zhang YN, Feng YL, Liu Q, et al: Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): A phase 2, single-arm, prospective study. Lancet Oncol. 19:1239–1246. 2018.PubMed/NCBI View Article : Google Scholar
33	Pinilla-Ibarz J, Cortes J and Mauro MJ: Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications. Cancer. 117:688–697. 2011.PubMed/NCBI View Article : Google Scholar
34	United States Department of Health Human Services: Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, 2017.
35	Higgins JP, Savović J, Page MJ, Elbers RG and Sterne JA: Assessing risk of bias in a randomized trial. Cochrane Handbook for systematic reviews of interventions, pp205-228, 2019.
36	Fei-Ling A, Kui-Ru H, Yu-Lin S, Yu-Tong W, Jian Z, Xue-Wei W and Xia W: Quality assessment of cohort studies literature on Chinese smoking by using Newcastle-Ottawa-Scale. Chin J Dis Control Prevention. 25:722–729. 2021.
37	Fahmy O, Fahmy UA, Alhakamy NA and Khairul-Asri MG: Single-port versus Multiple-port Robot-assisted radical prostatectomy: A systematic review and Meta-analysis. J Clin Med. 10(5723)2021.PubMed/NCBI View Article : Google Scholar
38	van Valkenhoef G and Kuiper J: Gemtc: Network meta-analysis using Bayesian methods. R Package version 0.8-8, 2020.
39	Treister-Goltzman Y and Peleg R: Fibromyalgia and mortality: A systematic review and meta-analysis. RMD Open. 9(e003005)2023.PubMed/NCBI View Article : Google Scholar
40	Rücker G, Schwarzer G, Krahn U, König J and Schwarzer MG: Package ‘netmeta’. Network Meta-analysis using Frequentist Methods (Version 07-0). 1:08–02. 2015.
41	Shim SR, Kim SJ, Lee J and Rücker G: Network meta-analysis: Application and practice using R software. Epidemiol Health. 41(e2019013)2019.PubMed/NCBI View Article : Google Scholar
42	Lai Z, Liang R, Wu Q and Zhang J: Short-term efficacy of apatinib in advanced ovarian cancer after failure of second-line treatment. J Pract Oncol. 33:309–312. 2018.
43	Sun S, Zhai D and Yu C: Clinical study on the efficacy of apatinib treatment for advanced ovarian cancer after second-line chemotherapy failure. Ann Oncol. 29(viii347)2018.
44	Li JZA, Jiang Q, Zheng F and Zhu H: Efficacy and safety of apatinib treatment in platinum-resistant recurrent epithelial ovarian cancer: A real world study. Drug Des Devel Ther. 13:3913–3918. 2019.PubMed/NCBI View Article : Google Scholar
45	Yang M, Liu X, Zhang C, Liao F, Li Z, Luo X, Sun Y and Chen C: A study of efficacy and safety with apatinib or apatinib combined with chemotherapy in recurrent/advanced ovarian cancer patients. Cancer Manag Res. 11:8869–8876. 2019.PubMed/NCBI View Article : Google Scholar
46	Sun L, Liu X, Yu H, Wang K and Liu W: Evaluation of efficacy and safety of apatinib for patients with recurrent epithelial ovarian cancer. Chin J Clin Oncol. 46:627–630. 2019.
47	Xia X and Zhao W: Apatinib monotherapy in patients with advanced ovarian cancer after platinum resistance: A prospective, exploratory study. Int J Gynecological Cancer. 29(A542)2019.
48	Miao Y, Liu H, Yi Q, et al: Clinical efficacy of Apatinib combined with intraperitoneal injection of cisplatin in treatment of elderly advanced ovarian cancer patients with malignant ascites. Anti Tumor Pharmacy. 9:291–295. 2019.
49	Zhang J, Li A, Jiang Q, Zheng F and Zhu H: Efficacy and safety of apatinib treatment in platinum-resistant recurrent epithelial ovarian cancer: A real world study. Drug Des Devel Ther. 13:3913–3918. 2019.PubMed/NCBI View Article : Google Scholar
50	Zhang W, Ma X, Zhang Q and Tan Y: Clinical efficacy of apatinib combined with tegiol in the treatment of platinum-resistant or platinum-refractory advanced ovarian cancer. J Baotou Med Coll. 35:33–34, 36. 2019.
51	Li Y, Jin X and Wang H, Liu Y and Wang H: Clinical efficacy of irinotecan combined with apatinib in the treatment of Platinum-and Taxane-resistant advanced ovarian cancer. J Med Res. 49:136–140. 2020.
52	Li Y, Liu J, Li J and Piao J: Efficacy of apatinib combined with etoposide in the treatment of patients with platinum-resistant recurrent ovarian cancer. J Chin J Primary Med Pharmacy. 27:2453–2457. 2020.PubMed/NCBI View Article : Google Scholar
53	Qiu M, Wu J, Ye X, Zhang Q and Yin J: Clinical efficacy and prognosis of chemotherapy regimen of apatinib combined with paclitaxel in the treatment of advanced ovarian cancer. Int J Clin Exp Med. 13:191–199. 2020.
54	Yan Z, Gu YY, Hu XD, Zhao Q, Kang HL, Wang M, Duan W and Guan Y: Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of the VEGFR2 polymorphism. Oncol Lett. 20:3035–3045. 2020.PubMed/NCBI View Article : Google Scholar
55	Yuan Y, Shi H and Xing L: Clinical observation of apatinib mesylate combined with etoposide capsules in the treatment of platinum-resistant recurrent and metastatic ovarian cancer. World Latest Med Information. 20:214–215. 2020.
56	Song X and Wang X: Analysis of the effect of apatinib mesylate in the treatment of platinum-resistant or refractory ovarian cancer. Chin Remedies Clin. 21:1185–1187. 2021.
57	Wang Z, Huang Y, Long L, Zhou L, Huang Y, Gan L, Pu A, Li S and Xie R: Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression. J Ovarian Res. 14(91)2021.PubMed/NCBI View Article : Google Scholar
58	Guo J, Liu D, Wang N, et al: Effect of apatinib on platinum resistance in patients with ovarian cancer after recurrence. J Anhui Med Pharmaceutical J. 26:603–606. 2022.
59	Pan Z, Luo Z, He H, Chen Y, Zhao B, Yang Z and Li L: Efficacy and safety of apatinib in the treatment of advanced platinum-resistant recurrent epithelial ovarian cancer: A retrospective study. J Clin Oncol. 40(e17594)2022.
60	Tang J, Han Z, Liu W, Wang HM, Zhao Y, Ge Y and Qin XB: Application of apatinib combined with pemetrexed in treatment of platinum-resistant recurrent ovarian cancer. Chi J Sch Doctor. 36:171–173, 188. 2022.
61	Wang T, Tang J, Yang H, Yin R, Zhang J, Zhou Q, Liu Z, Cao L, Li L, Huang Y, et al: Effect of Apatinib Plus Pegylated liposomal doxorubicin vs Pegylated liposomal doxorubicin alone on platinum-resistant recurrent ovarian cancer: The APPROVE randomized clinical trial. JAMA Oncol. 8:1169–1176. 2022.PubMed/NCBI View Article : Google Scholar
62	Wu Y and Chen L: Efficacy and safety of apatinib mesylate combined with etoposide in the treatment of platinum-resistant recurrent ovarian cancer. Eval Analysis Drug Use Hosp China. 22:1326–1329, 1333. 2022.PubMed/NCBI View Article : Google Scholar
63	Yan J and He G: Analysis of the clinical efficacy of apatinib combined with paclitaxel monotherapy in patients with recurrent platinum-resistant ovarian cancer. China Practical Med. 17:133–135. 2022.
64	Pan Z, Luo Z, He H, Chen Y, Zhao B, Yang Z and Li L: Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer. J Ovarian Res. 16(44)2023.PubMed/NCBI View Article : Google Scholar
65	Yang H, Geng A, Wang Z and Wu C: Efficacy and safety of apatinib combined with liposomal doxorubicin or paclitaxel versus liposomal doxorubicin or paclitaxel monotherapy in patients with recurrent platinum-resistant ovarian cancer. J Obstet Gynaecol Res. 49:1611–1619. 2023.PubMed/NCBI View Article : Google Scholar
66	Zhu F and Zhuang L: Evaluation of the efficacy and safety of apatinib combined with chemotherapy in patients with platinum-sensitive recurrent ovarian cancer. Anti Tumor Pharmacy. 12:521–527. 2022.
67	Wang J, Shen Y, Chen J, Chen X, Guan Q, Liu Q, Xu J, Xu Y, Zhang B, Zhang H, et al: 202TiP A single-arm, open, multicenter and exploratory clinical study of fluzopari combined with apatinib in pts with platinum-sensitive relapsed ovarian cancer first-line treated with a PARP inhibitor. Ann Oncol. 33 (Suppl 9)(S1513)2022.
68	Wang Z, Chen W, Zuo L, Xu M, Wu Y, Huang J, Zhang X, Li Y, Wang J, Chen J, et al: The Fibrillin-1/VEGFR2/STAT2 signaling axis promotes chemoresistance via modulating glycolysis and angiogenesis in ovarian cancer organoids and cells. Cancer Commun (Lond). 42:245–265. 2022.PubMed/NCBI View Article : Google Scholar
69	Guo J, Yue H, Wang Y, Du X, Saoudi M and Syarif A: Evaluation preparation of apatinib-loaded polymer nanoparticles and its effect in the treatment of advanced ovarian cancer. J Nanosci Nanotechnol. 21:1212–1219. 2021.PubMed/NCBI View Article : Google Scholar
70	Liu G, Wang C, He Y and Mingyan E: Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours. BMC Pharmacol Toxicol. 20(61)2019.PubMed/NCBI View Article : Google Scholar
71	Li L, Zheng J, Liu Z, Huang Y, Xiao J, Wang S, Yu Q, Zhang Q, Hu X, Zhao W, et al: Pre-treatment ¹⁸F-RGD uptake may predict adverse events during Apatinib Antiangiogenic therapy. Clin Oncol (R Coll Radiol). 34:e238–e245. 2022.PubMed/NCBI View Article : Google Scholar
72	Wu Z and Fang H: Efficacy of paclitaxel and S-1 combined with apatinib in the conversion therapy for unresectable advanced gastric cancer. J BUON. 26:1485–1490. 2021.PubMed/NCBI
73	Deng W, Wang J and Shi X: Value of low-dose apatinib combined with first-line chemotherapy in the conversion therapy of advanced gastric cancer. China J Modern Med. 33:20–24. 2023.
74	Xu X, Ye M, Zhao E, Li L and Meng Y: Efficacy and safety of apatinib in the treatment of advanced ovarian cancer: A meta-analysis. Chin J Health Care Med. 23:634–637. 2021.PubMed/NCBI View Article : Google Scholar
75	Xu X: Comparison of the efficacy and safety of Bevacizumab and apatinib in the treatment of recurrent cervical cancer. Pract J Cancer. 37:679–682. 2022.
76	Narod SA and Offit K: Prevention and management of hereditary breast cancer. J Clin Oncol. 23:1656–1663. 2005.PubMed/NCBI View Article : Google Scholar
77	Lasta JL, Groto AD and Brandalize APC: Assessment of medical knowledge toward genetic testing for individuals with hereditary breast and ovarian cancer syndrome in Brazil. Prev Med Rep. 35(102356)2023.PubMed/NCBI View Article : Google Scholar
78	Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Goggins M, Hutton ML, et al: Genetic/Familial High-risk assessment: Breast, ovarian, and pancreatic, Version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 19:77–102. 2021.PubMed/NCBI View Article : Google Scholar